CACLP Booth NO. A2-0115

It was reported on September 9 that Lanyu Bio, a domestic high-tech enterprise for in vitro diagnostics, announced the completion of the D2 round of financing of nearly CNY 100 million. This round of financing was led by government funds, and Yikai Capital served as the exclusive financial advisor for this round.

This is after the company received hundreds of millions of D1 rounds of investment from CICC Capital and Dynamic Balance Capital in the first half of this year, Lanyu Bio has once again obtained capital blessing. This round of funds will be mainly used to expand the local and overseas market layout and accelerate the company's channel network sinking to the terminal.

Nanjing Lanyu Biotechnology Co., Ltd. was established in 2016. It is a high-tech enterprise dedicated to the research and development, production, application and service integration of human in vitro diagnostic reagents and related instruments in the biomedical field.

In terms of business, while overcoming the technical barriers of active microfluidics, Lanyu Bio has completed the exploration of multiple detection platforms such as immunofluorescence, microfluidics, chemiluminescence, electrochemistry, and molecular diagnosis. The center has developed nearly 500 varieties of products, covering nearly 90% of diseases such as cardiovascular and cerebrovascular, infections, tumors, etc., with the characteristics of micro, simple, fast and accurate, providing comprehensive solutions for medical institutions at all levels, and exporting nearly 100 It can meet the medical needs of more than 30,000 medical institutions and more than 200 million families in various countries and regions.

Xu Xingshang, chairman and general manager of Lanyu Biology, said: After the epidemic, more home testing needs have arisen. With the transformation of health concepts, the diagnosis and treatment model centered on hospitals and symptomatic treatment has gradually developed to the scene of daily health care in communities and families. 5G Under these conditions, telemedicine is no longer limited by technical conditions. In the future, more products of Lanyu will be applied in home scenarios and connected to hospital terminals through the network, which can better help hospitals divert patients and assist in hierarchical diagnosis and treatment.

Focusing on the pain points of the backwardness of the informatization level of primary medical care, Lanyu Bio has become a one-stop service provider for the grass-roots level through Internet medical care, and has created a grass-roots diagnosis and treatment solution for primary medical institutions with the empowerment of informatization as an entry point. Gradually provide new products such as grassroots follow-up kits and home diagnosis and treatment kits, promote the implementation of information technology at the grassroots level, and promote the normalization of smart medical care, thereby creating new business explosion points.